Article (Scientific journals)
Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study
Linke, Axel; Wenaweser, Peter; Gerckens, Ulrich et al.
2014In European Heart Journal
Peer Reviewed verified by ORBi
 

Files


Full Text
ADVANCE Study.pdf
Publisher postprint (619.17 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
aortic stenosis; transcatheter aortic valve implantation; CoreValve; valvuloplasty; mortality
Abstract :
[en] Aim Transcatheter aortic valve implantation has become an alternative to surgery in higher risk patients with symptomatic aortic stenosis. The aim of the ADVANCE study was to evaluate outcomes following implantation of a self-expanding transcatheter aortic valve system in a fully monitored, multi-centre ‘real-world’ patient population in highly experienced centres. Methods and results Patients with severe aortic stenosis at a higher surgical risk inwhomimplantation of theCoreValve Systemwas decided by the Heart Teamwere included. Endpointswere a composite of major adverse cardiovascular and cerebrovascular events (MACCE; all-cause mortality, myocardial infarction, stroke, or reintervention) and mortality at 30 days and 1 year. Endpoint- related eventswere independently adjudicated based on Valve AcademicResearch Consortiumdefinitions.Atotal of 1015 patients [mean logistic EuroSCORE 19.4+12.3% [median (Q1,Q3), 16.0% (10.3, 25.3%)], age 81+6 years] were enrolled. Implantation of the CoreValve System led to a significant improvement in haemodynamics and an increase in the effective aortic valve orifice area. At 30 days, theMACCErate was 8.0% (95% CI: 6.3–9.7%), all-cause mortalitywas 4.5% (3.2–5.8%), cardiovascular mortality was 3.4% (2.3–4.6%), and the rate of stroke was 3.0% (2.0–4.1%). The lifethreatening or disabling bleeding rate was 4.0% (2.8–6.3%). The 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and stroke were 21.2% (18.4–24.1%), 17.9% (15.2–20.5%), 11.7% (9.4–14.1%), and 4.5% (2.9–6.1%), respectively. The 12-month rates of all-cause mortality were 11.1, 16.5, and 23.6% among patients with a logistic Euro- SCORE ≤10%, EuroSCORE 10–20%, and EuroSCORE .20% (P , 0.05), respectively. Conclusion The ADVANCE study demonstrates the safety and effectiveness of the CoreValve System with low mortality and stroke rates in higher risk real-world patients with severe aortic stenosis.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Linke, Axel
Wenaweser, Peter
Gerckens, Ulrich
Tamburino, Corrado
Bosmans, Johan
Bleiziffer, Sabine
Blackman, Daniel
Schäfer, Ulrich
Müller, Ralf
Sievert, Horst
Sondergaard, Lars
Klugmann, Silvio
Hoffmann, Rainer
Tchétché, Didier
Colombo, Antonio
LEGRAND, Victor ;  Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Bedogni, Francesco
lePrince, Pascal
Schuler, Gerhard
Mazzitelli, Domenico
Eftychiou, Christos
Frerker, Christian
Boekstegers, Peter
Windecker, Stephan
Mohr, Friedrich-Wilhelm
Woitek, Felix
Lange, Rüdiger
Bauernschmitt, Robert
Brecker, Stephen
More authors (19 more) Less
Language :
English
Title :
Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study
Publication date :
28 March 2014
Journal title :
European Heart Journal
ISSN :
0195-668X
eISSN :
1522-9645
Publisher :
Oxford University Press, Oxford, United Kingdom
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 06 July 2014

Statistics


Number of views
210 (2 by ULiège)
Number of downloads
467 (2 by ULiège)

Scopus citations®
 
189
Scopus citations®
without self-citations
127
OpenCitations
 
167

Bibliography


Similar publications



Contact ORBi